



Press release

Crossject signs a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense (DOD)

Dijon, 14 October 2019

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of combined drugs for use in emergency situations, is announcing the signing of a cooperative research and development agreement.

Crossject and the U.S. Department of Defense's (DOD) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), signed a Cooperative Research and Development Agreement (CRADA) on Midazolam Autoinjector.

Patrick Alexandre, Crossject's CEO, commented, *"We are very pleased to enter this Cooperative Research and Development Agreement with the U.S. Department of Defense, after their diligence in Dijon last July. There is obviously a joint area of interest in the protection of troops against attacks with nerve agents. The U.S. Food and Drug Administration (FDA) and the DOD align their efforts routinely¹ to foster the development and use of specific pharmaceutical products."*

¹ <https://www.fda.gov/news-events/press-announcements/fda-and-dod-formalize-collaboration-advance-medical-products-support-american-military-personnel>



Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CM-CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cmcic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Christelle Distinguin +33 (0)3 80 43 54 89
christelle.distinguin@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.